Immunotherapy Significantly Extends Survival in Patients with Rare Desmoplastic Melanoma

Recent research led by UCLA investigators has demonstrated the promising potential of immunotherapy, specifically pembrolizumab, in treating advanced desmoplastic melanoma—a rare and highly aggressive type of skin cancer. This form of melanoma often develops in sun-damaged skin areas and features numerous genetic mutations, making it particularly challenging to treat.

The study, published in Nature Medicine, revealed that nearly 90% of patients experienced substantial tumor reduction or complete disappearance after treatment with pembrolizumab, an immune checkpoint inhibitor targeting PD-1. This drug works by helping the immune system recognize and attack cancer cells more effectively.

In a multicenter clinical trial called SWOG S1512, researchers focused on patients with unresectable metastases who received pembrolizumab every three weeks over two years. Results showed that 37% of these patients achieved complete tumor remission, and overall, 89% experienced tumor shrinkage or disappearance. Notably, responses were often rapid, with some patients showing tumor reduction within two months, and many maintaining remission long after stopping treatment.

The safety profile was manageable, although some older patients with additional health issues experienced side effects that led to early discontinuation. Despite this, the treatment's efficacy remained unaffected.

Senior author Dr. Antoni Ribas emphasized that these findings underscore the high response rates of desmoplastic melanoma to anti-PD-1 therapies, providing a less invasive and more targeted treatment option compared to surgery or radiation. This breakthrough offers hope to patients with this rare cancer subtype, narrowing the gap in treatment options.

The success of this immunotherapy approach marks a significant advancement, transforming prospects for patients with advanced desmoplastic melanoma and potentially other challenging melanoma variants. These findings advocate for the broader use of immune checkpoint inhibitors as a first-line treatment, especially given their low toxicity and high efficacy.

For more details, the full study can be accessed via Nature Medicine: link.